Hainan Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Poly Pharmaceutical"), through its holding subsidiary Anhui Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Poly"), has recently received the Certificate of Suitability to the European Pharmacopoeia (hereinafter referred to as the "CEP Certificate") for the active pharmaceutical ingredient Voriconazole, issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM").
Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as "Poly Pharm") and its holding subsidiary, Anhui Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Poly"), have recently received the Certificate of Suitability to the European Pharmacopoeia (hereinafter referred to as the "CEP Certificate") for the active pharmaceutical ingredient (API) Sodium Nitroprusside, issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM").
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received Certificate of Suitability (CEP) of gadobutrol API issued by European Directorate for the Quality of Medicines & HealthCare (EDQM).
Anhui Poly Pharm. Co., Ltd. (hereinafter referred to as “Anhui Poly”), a holding subsidiary of Hainan Poly Pharm. Co., Ltd. (hereinafter referred to as “Poly Pharm.”), has recently received written confirmation for active substance exported to EU (hereinafter referred to as “WC”) of gadobutrol API and certificate of a pharmaceutical product (hereinafter referred to as “COPP”) of cyclophosphamide API issued by Anhui NMPA.
From Milan to the ancient capital Xi'an, after participating in the 35th CPHI Milan 2024 (World Pharmaceutical API Exhibition) held at the Milan Exhibition Center in Italy, Poly witnessed the grand opening of the 91st CPHI/Intermediates/Packaging/Equipment Fair from October 16-18, 2024.
